Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1036P represents a processed pseudogene of the U6 small nuclear RNA gene family[2]. U6 snRNA is a highly conserved, essential component of the spliceosome, involved in catalyzing the excision of introns from pre-mRNA in eukaryotic nuclei[1][3]. However, RNU6-1036P, like other U6 pseudogenes, is not transcribed into a functional RNA product[4]. Such pseudogenes are generated by retrotransposition mechanisms (predominantly LINE-1 mediated)[4], and are considered functionless genomic relics that do not encode proteins nor contribute to spliceosome assembly or function. Their presence in the genome reflects the evolutionary history and retrotranspositional activity, but they are not known to be involved in disease, cell signaling, or as pharmacologic targets[4][5]. There is nothing incorrect about the entry itself, but it should not be interpreted as a functional therapeutic target, receptor, enzyme, transporter, or regulator. It is best classified as a non-coding RNA pseudogene with no direct clinical, pharmacological, or disease relevance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1036, pseudogene (RNU6-1036P).